Hester Biosciences Q2 FY27: revenue up 37.9% to ₹98 Cr, net profit up 44.1% to ₹21 Cr
Results · Finvezto · 5 Nov 2026 · Hester Biosciences (HESTERBIO)
Results Q2 FY27, ₹ Cr
| Q2 FY27 | ₹ Cr | QoQ | YoY |
|---|---|---|---|
| Revenue | 98 | +26.8% | +37.9% |
| Operating profit | 33 | +43.4% | +179.5% |
| Net profit | 21 | -78.7% | +44.1% |
| Operating margin | 33.4% | +3.9 pp | +16.9 pp |
| Net margin | 21.0% | -104.2 pp | +0.9 pp |
Key points
- For the quarter ended 30 September 2026 (Q2 FY27), Hester Biosciences reported consolidated revenue from operations of Rs 97.91 crore (up 38% YoY from Rs 70.97 crore), EBITDA of Rs 36.52 crore (up 55% YoY from Rs 23.60 crore), and profit after tax of Rs 20.63 crore (up 44% YoY from Rs 14.33 crore). NSE filing
- The board also approved extending an unsecured loan of USD 1 million to wholly-owned subsidiary Hester Biosciences Africa Limited for working capital and business purposes. NSE filing
- Standalone revenue increased by 28% in Q2 FY27 and 21% in H1 FY27, with net profit more than doubling by 131% in Q2 and 108% in H1 over the prior year. Earnings call
- Gross profit margin and EBITDA margin stood at 78% and 35% respectively in both Q2 and H1 FY27, supported by a favorable product mix and operational discipline. Earnings call
What to watch
- Management on fy27 priorities: Looking ahead for the remainder of FY27, our priorities are to sustain poultry health care growth, strengthen biologicals business across poultry and Animal Health.
- Management on international operations: We will also work towards commercially viable path for Nepal and improved financial sustainability for Africa.
- Operating margin over the last 4 quarters (Dec 25, Mar 26, Jun 26, Sep 26): 23.0%, 34.3%, 29.5%, 33.4%.
- Net profit over the last 4 quarters (Dec 25, Mar 26, Jun 26, Sep 26), ₹ Cr: 9, 17, 97, 21.
Links
NSE filing (PDF) · Company page · Results tracker
Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630.